Aurinia Pharmaceuticals (AUPH) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.56%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.17 per share when it actually produced a loss of $0.09, delivering a surprise of 47.06%.Over the last four quarters, th ...

ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today provided an update on its 2023 fourth quarter and full year business performance, as well as a corporate update regarding the Company’s strategic review. This includes corporate actions designed to enhance shareholder value, including an exclusive focus on driving commercial execution of the LUPKYNIS® (voclosporin) business, and a significant share repurchase program. Effecti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________________________________ Form 10-K ___________________________________________________________________________________ ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_______ ...

Wall Street expects flat earnings compared to the year-ago quarter on higher revenues when Aurinia Pharmaceuticals (AUPH) reports results for the quarter ended December 2023. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 15, 2024, might help the stock move higher if these key nu ...

WINNIPEG, Manitoba, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSXV:KNE, OTCQB:KNBIF) (the "Company", "Kane" or "Kane Biotech") announces today that on February 20, 2024, the Company will hold a special meeting of its shareholders (the "Meeting") to consider the election of Dr. Robert Huizinga as an additional director of the Company. The information circular and other materials with respect to the Meeting will be filed on SEDAR+ by the Company in due course. Dr. Huizinga is currently the principa ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Jamie Harrell - Investor Relations Peter Greenleaf - Chief Executive Officer Joe Miller - Chief Financial Officer Conference Call Participants Farzin Haque - Jefferies Joseph Schwartz - Leerink Partners Olivia Brayer - Cantor Fitzgerald Justin Kim - Oppenheimer and Company Ed Arce - HC Wainwright Sahil Dhingra - RBC Capital Markets David Martin - Bloom Burton Operator Greetings. Welco ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________________________________ FORM 10-Q _____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |------------------------------------------------------------------|------------------ ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Jamie Harrell - Investor Relations Peter Greenleaf - Chief Executive Officer Joe Miller - Chief Financial Officer Conference Call Participants Will Soghikian - Leerink Partners Ed Arce - H.C. Wainwright David Martin - Bloom Burton Farzin Haque - Jefferies Justin Kim - Oppenheimer Operator Greetings. And welcome to Aurinia Pharmaceuticals Incorporated Second Quarter 2023 Earnings Call. A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________________________________ FORM 10-Q _____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |------------------------------------------------------------------|----------------------- ...

Start Time: 08:30 January 1, 0000 9:27 AM ET Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2023 Earnings Conference Call May 04, 2023, 08:30 AM ET Company Participants Peter Greenleaf - President and CEO Joe Miller - CFO Jamie Harrell - Head of IR Conference Call Participants Olivia Brayer - Cantor Fitzgerald Farzin Haque - Jefferies Stacy Ku - TD Cowen Justin Kim - Oppenheimer Ed Arce - H.C. Wainwright David Martin - Bloom Burton Will Soghikian - SVB Securities Sahil Dhingra - RBC Capital Markets Operator ...